These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16223370)

  • 21. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.
    Marchetti A; Buttitta F; Bertacca G; Zavaglia K; Bevilacqua G; Angelucci D; Viacava P; Naccarato A; Bonadio A; Barassi F; Felicioni L; Salvatore S; Mucilli F
    J Pathol; 2001 Sep; 195(2):186-90. PubMed ID: 11592097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human tissue polypeptide antigen in breast cancer.
    Nemoto T; Constantine R; Chu TM
    J Natl Cancer Inst; 1979 Dec; 63(6):1347-50. PubMed ID: 292806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of dot-immunobinding assay for carcinoembryonic antigen determination in nipple discharge as an adjunct in the diagnosis of early breast cancer. Research Group for Carcinoembryonic Antigen in Nipple Discharge.
    Mori T; Inaji H; Higashiyama M; Yayoi E; Izuo M; Ueno E; Enomoto K; Kasumi F; Sakamoto G; Tominaga T
    Jpn J Clin Oncol; 1989 Dec; 19(4):373-9. PubMed ID: 2691732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
    Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
    Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
    Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
    Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA.
    Zach O; Kasparu H; Krieger O; Hehenwarter W; Girschikofsky M; Lutz D
    J Clin Oncol; 1999 Jul; 17(7):2015-9. PubMed ID: 10561252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
    Dong J; Sun G; Zhu H
    Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
    Hayes DF; Zurawski VR; Kufe DW
    J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
    Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
    Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum carcinoembryonic antigen as a tumour marker in patients with endometrial cancer.
    Hashiguchi Y; Kasai M; Fukuda T; Ichimura T; Yasui T; Sumi T
    Curr Oncol; 2016 Oct; 23(5):e439-e442. PubMed ID: 27803603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new biomarker in monitoring breast cancer: CA 549.
    Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
    J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2004; 51(55):136-41. PubMed ID: 15011849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.
    Albanopoulos K; Armakolas A; Konstadoulakis MM; Leandros E; Tsiompanou E; Katsaragakis S; Alexiou D; Androulakis G
    Am J Gastroenterol; 2000 Apr; 95(4):1056-61. PubMed ID: 10763959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.